RxDoctor Payments Data

Shane Stephenson, MD

Family Medicine · Omaha, NENPI 1427369321

Payments from drug & device makers

$4,966in general payments, 2019–2025

Across 285 payments — averaging $17.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • AstraZeneca$403
  • Amgen$345
  • Lilly USA, LLC$322
  • Boehringer Ingelheim$295
  • Novo Nordisk$256
  • plus $2K from 39 others

What the payments were for

  • Food & beverage$4,948100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,966 in reported general payments places this provider in the 90th percentile of 981 family medicine providers in Nebraska.

See all family medicine providers in Nebraska

Medicare billing

Part B allowed, 2024
$216,610
Medicare patients
394
Services billed
5,978

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide103$103,771
OzempicSemaglutide98$100,539
EliquisApixaban86$91,526
FarxigaDapagliflozin Propanediol74$69,565
JardianceEmpagliflozin42$55,103
MyrbetriqMirabegron37$27,267
Breztri AerosphereBudesonide/Glycopyr/Formoterol36$23,723
Tresiba Flextouch U-200Insulin Degludec31$23,350
LinzessLinaclotide16$22,810
JanuviaSitagliptin Phosphate16$20,166
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$18,695
Repatha SureclickEvolocumab21$13,897
BelsomraSuvorexant26$11,234
Repatha SyringeEvolocumab12$7,013
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$6,434

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$322$103,771103 claims
Novo NordiskOzempic$256$100,53998 claims
AstraZenecaFarxiga, Breztri Aerosphere$403$93,288110 claims
PfizerEliquis$95$91,52686 claims
Boehringer IngelheimJardiance, Stiolto Respimat$295$60,45953 claims
MerckJanuvia, Belsomra$98$31,40042 claims
Astellas Pharma US IncMyrbetriq$104$27,26737 claims
AbbVieLinzess$1,035$22,81016 claims
GSKTrelegy Ellipta$15$18,69520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 981 family medicine providers in Nebraska.

Other family medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →